Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Nivolumab 5Cyclophosphamide 5pembrolizumab 4Ipilimumab 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Blood Specimen Collection 2trametinib 1tebentafusp 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1binimetinib 1belinostat 1avelumab 1Vorinostat 1Valproic Acid 1Tape Recording 1Sunitinib 1Spinal Puncture 1Practice Guidelines as Topic 1Pemetrexed 1Methods 1LY2940680 1Iodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × LY2940680 × 90 days × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡